At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
MAIA MAIA Biotechnology Inc.
Post-Mkt 04-08 16:49:15 EDT
1.24
+0.04
+3.33%
盘后1.23
-0.01-0.47%
16:40 EDT
High1.30Low1.23Vol611.12K
Open1.24D1 Closing1.20Amplitude5.82%
Mkt Cap75.23MTradable Cap68.97MTotal Shares60.67M
T/O770.69KT/O Rate1.10%Tradable Shares55.62M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

MAIA Biotechnology secures funding for clinical trial of ateganosine
TIPRANKS  ·  04-08 21:31
MAIA Biotechnology secures funding for clinical trial of ateganosine
Maia Biotechnology says $33 million stock offering fully funds Phase 3 NSCLC trial
Reuters  ·  04-08 21:02
Maia Biotechnology says $33 million stock offering fully funds Phase 3 NSCLC trial
MAIA Biotechnology Expects Recent $33 Million Capital Raise to Fully Fund Ongoing Pivotal Phase 3 Trial of Novel Telomere-Targeting Anticancer Therapy
GlobeNewswire  ·  04-08 21:00
MAIA Biotechnology Expects Recent $33 Million Capital Raise to Fully Fund Ongoing Pivotal Phase 3 Trial of Novel Telomere-Targeting Anticancer Therapy
Maia Biotechnology announces annual shareholder meeting in virtual format
Reuters  ·  04-07 21:03
Maia Biotechnology announces annual shareholder meeting in virtual format
MAIA Biotechnology Awards Executive Bonuses After Successful Financing
TIPRANKS  ·  04-03
MAIA Biotechnology Awards Executive Bonuses After Successful Financing
Maia Biotechnology CEO receives one-time $0.3 million bonus tied to capital raise
Reuters  ·  04-03
Maia Biotechnology CEO receives one-time $0.3 million bonus tied to capital raise
MAIA Highlights Promising Phase 2 NSCLC Survival Outcomes
TIPRANKS  ·  04-01
MAIA Highlights Promising Phase 2 NSCLC Survival Outcomes
BRIEF-Maia Biotechnology Reports Overall Survival Exceeding Two Years For Eight Patients In Ongoing Phase 2 Clinical Trial In Non-Small Cell Lung Cancer
Reuters  ·  03-31
BRIEF-Maia Biotechnology Reports Overall Survival Exceeding Two Years For Eight Patients In Ongoing Phase 2 Clinical Trial In Non-Small Cell Lung Cancer
MAIA Showcases THIO-101 NSCLC Data at ELCC 2026
TIPRANKS  ·  03-27
MAIA Showcases THIO-101 NSCLC Data at ELCC 2026
MAIA Biotechnology Q4 EPS $(0.08) Beats $(0.13) Estimate
Benzinga  ·  03-24
MAIA Biotechnology Q4 EPS $(0.08) Beats $(0.13) Estimate
Maia Biotechnology FY 2025 net loss was USD 22.4 million as R&D expenses rose 45% to USD 14.5 million
Reuters  ·  03-23
Maia Biotechnology FY 2025 net loss was USD 22.4 million as R&D expenses rose 45% to USD 14.5 million
MAIA Biotechnology Completes $30 Million Public Stock Offering
TIPRANKS  ·  03-05
MAIA Biotechnology Completes $30 Million Public Stock Offering
BRIEF-Maia Biotechnology Inc Enters Underwriting Agreement With Konik Capital Partners - SEC Filing
Reuters  ·  03-05
BRIEF-Maia Biotechnology Inc Enters Underwriting Agreement With Konik Capital Partners - SEC Filing
Maia Biotechnology Inc - to Issue 20,000,000 Shares of Common Stock in Public Offering - SEC Filing
THOMSON REUTERS  ·  03-05
Maia Biotechnology Inc - to Issue 20,000,000 Shares of Common Stock in Public Offering - SEC Filing
Maia Biotechnology Inc - on March 2, Co Enters Underwriting Agreement With Konik Capital Partners on March 2, 2026 - SEC Filing
THOMSON REUTERS  ·  03-05
Maia Biotechnology Inc - on March 2, Co Enters Underwriting Agreement With Konik Capital Partners on March 2, 2026 - SEC Filing
MAIA Biotechnology Announces Closing of $30 Million Underwritten Public Offering of Common Stock
GlobeNewswire  ·  03-05
MAIA Biotechnology Announces Closing of $30 Million Underwritten Public Offering of Common Stock
BUZZ-MAIA Biotechnology plunges after $30 million share sale
Reuters  ·  03-03
BUZZ-MAIA Biotechnology plunges after $30 million share sale
MAIA Biotechnology 20M share Spot Secondary priced at $1.50
TIPRANKS  ·  03-03
MAIA Biotechnology 20M share Spot Secondary priced at $1.50
MAIA Biotechnology announces common stock offering, no amount given
TIPRANKS  ·  03-03
MAIA Biotechnology announces common stock offering, no amount given
MAIA Biotechnology Announces Proposed Underwritten Public Offering of Common Stock and Pre-Funded Warrants
GlobeNewswire  ·  03-03
MAIA Biotechnology Announces Proposed Underwritten Public Offering of Common Stock and Pre-Funded Warrants

Introduction

Company Name.
MAIA Biotechnology Inc.
Affiliated Markets:
AMEX
Listing Date:
--
Main Business:
MAIA Biotechnology, Inc., a clinical stage biotechnology company, engages in the discovery, development, and commercialization of therapies targeting cancer. The company's lead product candidate is THIO, a telomere-targeting agent that is in Phase II clinical study to evaluate its activity in patients with non-small cell lung cancer. It is also developing second generation telomere targeting agents. MAIA Biotechnology, Inc. was incorporated in 2018 and is headquartered in Chicago, Illinois.
Issue price:
--